A recent survey reported that four out of every five Canadians are in favor of the therapeutic use of psilocybin for individuals who suffer from a terminal condition; those respondents urge the government to establish a regulatory framework to allow its use in these circumstances.
The poll was carried out by Nanos Research and commissioned by the Canadian Psychedelic Association (“CPA”). For the survey, more than 1,000 Canadian adults were interviewed between June 30, 2021, and July 5, 2021.
More than 75% of the survey’s respondents stated that they supported the establishment of a legal regulatory model to facilitate the treatment, with 82% stating that they were in favor of psilocybin-assisted therapy for individuals with terminal ailments. Nearly 65% also stated that the psychedelic substance should be made available to patients who were eligible for its use under the Medical Assistance in Dying (“MAID”) rules.
CPA revealed that the next step would be to introduce its Memorandum of Regulatory Approval to parliament, as discussions with lawmakers signal support for the effort to regulate the therapeutic use of psilocybin for these patients. In a press release, CPA’s executive director Cory Firth stated that the memorandum was compiled by the best regulatory, legal and industry experts as well as researchers in Canada.
Psychedelics researcher Pamela Kryskow stated that the new survey results served as a go-ahead for Health Canada to pursue the psychedelic’s regulation. She explained that the proof of the substance’s therapeutic benefit was in both patient improvement and research, as a lot of positive clinical evidence has been reported which demonstrates that psilocybin-assisted therapy works very well in addressing various mental health conditions when other options aren’t as effective.
Thus far, Patty Hajdu, Canada’s Minister of Health, has granted the requests of some patients in end-of-life care to use the psychedelic for psychotherapy, with an official revealing that Canada would also permit some health-care professionals to consume and possess magic mushrooms to study them to evaluate and identify the potential for better treatment of patients.
Almost 70% of the survey’s respondents agreed that patients who suffer from post-traumatic stress disorder should be able to receive psilocybin therapy as treatment.
Canada has a 9.2% prevalence rate for PTSD, with estimates showing that more than 70% of Canadians have been exposed to at least one traumatic experience in their lifetime. Additionally, in comparison to 7% of Canadians who stated that they wouldn’t support politicians who supported the use of psilocybin-assisted therapy, about 20% revealed that they’d most likely support politicians who did.
This huge support for psychedelic therapy legalization shows Canada may be ahead of other countries in regard to progress in psychedelic policy reform. It is no wonder that many of the companies that have made significant steps in developing psychedelic medicines, such as Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), are based in Canada.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
